Loading...
•
Sep 30, 2022
Bausch + Lomb Q3 2022 Earnings Report
Announced third-quarter 2022 results, with revenue decline of 1% but organic revenues grew 5%, driven by growth across all segments, and a GAAP net loss of $18 million.
Key Takeaways
Bausch + Lomb reported a slight decrease in revenue, declining by 1% to $942 million, but experienced organic revenue growth of 5% across all segments. The company faced a GAAP net loss of $18 million, while adjusted EBITDA stood at $187 million.
Revenues of $942 Million
GAAP Net Loss Attributable to Bausch + Lomb Corporation of $18 Million
Adjusted EBITDA (non-GAAP) of $187 Million
Third-Quarter Reported Revenues Declined 1%, and Organic Revenues Grew 5%, Driven by Growth Across All Segments
Bausch + Lomb
Bausch + Lomb
Bausch + Lomb Revenue by Segment
Revenue by Segment
Vision Care Revenue
CapyFin.comSurgical Revenue
CapyFin.comPharmaceuticals Revenue
CapyFin.com Forward Guidance
Bausch + Lomb revised its revenue and Adjusted EBITDA guidance for the full year of 2022, due to the negative impact of foreign exchange. Adjusted EBITDA guidance also reflects a slower than expected ramp-up in manufacturing yield of Bausch + Lomb INFUSE®/ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.
Positive Outlook
- Full-year revenue range of $3.70 – $3.75 billion, reaffirming 4-5% organic growth
Challenges Ahead
- Full-year Adjusted EBITDA range of $715 – $755 million
- Due to the negative impact of foreign exchange
- Adjusted EBITDA guidance also reflects a slower than expected ramp-up in manufacturing yield of Bausch + Lomb INFUSE®/ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income